These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1395 related articles for article (PubMed ID: 32273594)

  • 21. Editorial: Information on the COVID-19 Pandemic continued.
    Rock G
    Transfus Apher Sci; 2020 Aug; 59(4):102854. PubMed ID: 32660893
    [No Abstract]   [Full Text] [Related]  

  • 22. Mesenchymal stem cells as a potential therapy for COVID-19.
    Liu S; Peng D; Qiu H; Yang K; Fu Z; Zou L
    Stem Cell Res Ther; 2020 May; 11(1):169. PubMed ID: 32366290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity, COVID-19 and immunotherapy: the complex relationship!
    Finelli C
    Immunotherapy; 2020 Oct; 12(15):1105-1109. PubMed ID: 32677493
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of SARS-CoV-2: How far have we reached?
    Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
    Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How blood from coronavirus survivors might save lives.
    Maxmen A
    Nature; 2020 Apr; 580(7801):16-17. PubMed ID: 32214238
    [No Abstract]   [Full Text] [Related]  

  • 26. COVID-19: Main therapeutic options.
    Hachfi W; Ben Lasfar N
    Tunis Med; 2020 Apr; 98(4):299-303. PubMed ID: 32395792
    [No Abstract]   [Full Text] [Related]  

  • 27. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Apr; 382(16):e58. PubMed ID: 32320592
    [No Abstract]   [Full Text] [Related]  

  • 29. COVID-19: the new challenge for rheumatologists. First update.
    Ferro F; Elefante E; Puxeddu I; Baldini C; Bartoloni E; Baratè C; Galimberti S; Talarico R; Mosca M; Bombardieri S
    Clin Exp Rheumatol; 2020; 38(3):373-382. PubMed ID: 32452355
    [No Abstract]   [Full Text] [Related]  

  • 30. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 31. COVID-19: an Immunopathological View.
    Kadkhoda K
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32321823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
    Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS
    Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ease restrictions on U.S. blood donations.
    Vasavda C; Ho BK; Snyder SH
    Science; 2020 May; 368(6494):957. PubMed ID: 32467382
    [No Abstract]   [Full Text] [Related]  

  • 34. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.
    Yager EJ
    Clin Immunol; 2020 Aug; 217():108496. PubMed ID: 32526272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How likely are COVID-19 interventions to benefit the sickest patients?
    Perner A; Tirupakuzhi Vijayaraghavan BK; Venkatesh B
    Intensive Care Med; 2020 Jul; 46(7):1441-1444. PubMed ID: 32519004
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel therapeutic approaches for treatment of COVID-19.
    Hossein-Khannazer N; Shokoohian B; Shpichka A; Aghdaei HA; Timashev P; Vosough M
    J Mol Med (Berl); 2020 Jun; 98(6):789-803. PubMed ID: 32494931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.
    Peng H; Gong T; Huang X; Sun X; Luo H; Wang W; Luo J; Luo B; Chen Y; Wang X; Long H; Mei H; Li C; Dai Y; Li H
    Stem Cell Res Ther; 2020 Jul; 11(1):291. PubMed ID: 32678017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.
    Rodriguez Z; Shane AL; Verkerke H; Lough C; Zimmerman MG; Suthar M; Wrammert J; MacDonald H; Wolf M; Clarke S; Roback JD; Arthur CM; Stowell SR; Josephson CD
    Blood Adv; 2020 Sep; 4(18):4278-4281. PubMed ID: 32915971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?
    Ledford H
    Nature; 2020 Aug; 584(7821):333-334. PubMed ID: 32782402
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.